PCMT1 and breast cancer: LITAF interacted with PCMT1 and promoted ubiquitination-mediated degradation of PCMT1, thereby inhibiting COX-2-mediated AA metabolism, reducing the proliferation of PTX-resistant BC cells, and enhancing the sensitivity of BC cells to PTX <i>in vivo</i>.<h4>Conclusion</h4>LITAF regulates the ubiquitination-mediated degradation of PCMT1 to inhibit COX-2-dependent AA metabolism, thereby enhancing the sensitivity of BC cells to PTX and providing a potential therapeutic strategy to overcome PTX resistance in BC.